The laryngeal mask airway for administration of surfactant in two neonates with respiratory distress syndrome

Brimacombe, J.; Gandini, Donna; Keller, Christian

doi:10.1046/j.1460-9592.2003.01173.x

Cited by 54 publications

(41 citation statements)

References 7 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(7) A year later, in Italy, eight newborns with RDS between 28 and 35 weeks were satisfactorily treated with surfactant using the classic LMA number 1. The procedure was well tolerated, with no need for sedatives or analgesics.…”

Section: Discussionmentioning

confidence: 99%

“…The use of nebulized surfactant still faces technical difficulties that prevent a final demonstration of its efficacy in vivo. In recent years, studies have been published describing the nasopharyngeal instillation of surfactant in the delivery room, (5) administration via a thin endotracheal catheter (6,7) or via a laryngeal mask airway (LMA). (2) The initial results in a small number of patients suggested LMA as a possible alternative route for surfactant treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Máscara laríngea ProSealTM como via de administração de surfactante no tratamento da síndrome do desconforto respiratório em recém-nascido pré-termo

Barbosa¹,

Marcatto²,

Silva³

et al. 2012

Rev. bras. ter. intensiva

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Máscara laríngea ProSealTM como via de administração de surfactante no tratamento da síndrome do desconforto respiratório em recém-nascido pré-termo

Barbosa¹,

Marcatto²,

Silva³

et al. 2012

Rev. bras. ter. intensiva

View full text Add to dashboard Cite

“…Case reports by Brimacombe et al [33], Trevisanuto et al [34], and Micaglio et al [35] demonstrate the feasibility of LMA for surfactant administration. A recent study reported a significant reduction of FiO 2 (at baseline: 0.41 ± 0.04 and after 3 h: 0.23 ± 0.01) in 4 neonates after surfactant administration by using an Air-Q self-pressurizing LMA (size 0.5).…”

Section: Surfactant Administrationmentioning

confidence: 95%

The Laryngeal Mask Airway and Its Use in Neonatal Resuscitation: A Critical Review of Where We Are in 2017/2018

Bansal

Caoci

Dempsey³

et al. 2017

Neonatology

View full text Add to dashboard Cite

fants, but the evidence is still insufficient to recommend the LMA instead of FM ventilation in the DR. There is, in particular, a dearth of evidence of the use of LMA in neonates born before 34 weeks' gestational age or weighing <1,500 g at birth. There were no reports on significant complications following the use of LMA; however, evidence is still limited regarding short-and long-term outcomes. We conclude that the limited currently available evidence suggests that the use of the LMA is a feasible and safe alternative to mask ventilation of late preterm and term infants in the DR. The potential use of LMA resuscitation, in particular for low-gestation and low-birth-weight infants, needs further study.

show abstract

“…In 2004, surfactant administration using a LMA was first described in a case report by Brimacombe et al [54]. A pilot randomized controlled trial in 26 preterm infants with birth weight >1,200 g compared surfactant given by LMA to CPAP and found a marked decrease in oxygen requirement in infants who received surfactant via LMA [55].…”

Section: New Techniques Of Surfactant Administrationmentioning

confidence: 99%

Surfactant for Respiratory Distress Syndrome: New Ideas on a Familiar Drug with Innovative Applications

Niemarkt¹,

Hütten²,

Kramer³

2017

Neonatology

View full text Add to dashboard Cite

In the last 4 decades, advances in neonatology have led to a significant increase in the survival of preterm infants. One of the biggest advances was the introduction of surfactant replacement therapy for the treatment of respiratory distress syndrome. This is the main cause of respiratory insufficiency in preterm infants and is one of the major causes of perinatal morbidity and mortality. Surfactant replacement therapy is already a well-investigated and established therapy in neonatology. However, surfactant replacement therapy has progressed and been refined over recent decades, especially with the increasing care for preterm infants born before 26 weeks' gestational age and the recent clinical focus on avoiding mechanical ventilation. Clinical evidence is evolving on new types of surfactant, surfactant dosages, co-medication given before, with, or after surfactant replacement, and new technical advances regarding the mode of administration.

show abstract

The laryngeal mask airway for administration of surfactant in two neonates with respiratory distress syndrome

Abstract: We report the successful use of the Classic laryngeal mask airway to provide brief access to the intratracheal space for the administration of surfactant in two neonates with respiratory distress syndrome.

Cited by 54 publications

References 7 publications

Máscara laríngea ProSealTM como via de administração de surfactante no tratamento da síndrome do desconforto respiratório em recém-nascido pré-termo

Máscara laríngea ProSealTM como via de administração de surfactante no tratamento da síndrome do desconforto respiratório em recém-nascido pré-termo

The Laryngeal Mask Airway and Its Use in Neonatal Resuscitation: A Critical Review of Where We Are in 2017/2018

Surfactant for Respiratory Distress Syndrome: New Ideas on a Familiar Drug with Innovative Applications

Contact Info

Product

Resources

About